FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to derivatives of adamantine of the formula (I): 
wherein D represents -CH2 or -CH2-CH2; E represents -C(O)NH or -NHC(O); each R1 and R2 represents independently hydrogen atom or halogen atom but R1 and R2 can't mean hydrogen atom simultaneously; R3 represents group of the formula: -R4-X-R5 (II) wherein R4 represents (C1-C6)-alkyl group; X represents oxygen or sulfur atom or the group NR13; R5 represents (C1-C6)-alkyl or (C2-C6)-alkenyl and each of them can be optionally substituted with at least one substitute taken among halogen atom, hydroxyl, di-(C1-C6)-alkylamino-group, -Y-R6, 
, and 5- or 6-membered heteroaromatic ring comprising 1-4 heteroatoms taken independently among nitrogen atom wherein heteroaromatic ring can be optionally substituted with at least one (C1-C6)-alkyl; Y represents oxygen or sulfur atom or the group -NH; R6 represents the group -R7Z wherein R7 represents (C2-C6)-alkyl group and Z represents -OH; when Y represents oxygen or sulfur atom or the group -NH then R6 represents additionally hydrogen atom, (C1-C6)-alkyl, (C1-C6)-alkylcarbonyl; R13 represents hydrogen atom, (C3-C8)-cycloalkyl, (C3-C8)-cycloalkylmethyl; or R13 represents (C1-C6)-alkyl group optionally substituted with at least one hydroxyl, or to its pharmaceutically acceptable salts or solvates. These compounds are effective antagonists of P2X7 receptors and can be used in treatment of rheumatic arthritis or lung chronic obstructive disease. Also, invention describes methods for preparing these compounds, pharmaceutical composition comprising indicated compounds, method for preparing pharmaceutical composition and their using in therapy.
EFFECT: improved preparing and treatment methods, valuable medicinal properties of compounds and composition.
19 cl, 1 tbl, 77 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF ADAMANTANE, METHOD FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS FOR TREATMENT | 2000 |
|
RU2254333C2 |
| DERIVATIVES OF ADAMANTANE, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, METHOD OF ITS PREPARING AND METHOD OF EFFECT ON IMMUNE SUPPRESSION | 1998 |
|
RU2197477C2 |
| PHARMACEUTICAL COMPOSITION, CONTAINING ANTAGONIST P2X OF RECEPTOR AND FACTOR OF TUMOUR NECROSIS α | 2004 |
|
RU2350354C2 |
| PHARMACEUTICAL COMPOSITION, CONTAINING ANTAGONIST OF P2X-RECEPTOR AND NONSTEROID ANTIINFLAMMATORY MEDICAL PRODUCT | 2004 |
|
RU2338556C2 |
| 8-CARBAMOYL-2-(2,3-DI-SUBSTITUTED PYRID-6-YL)-1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS-INDUCING AGENTS FOR CANCER TREATMENT | 2012 |
|
RU2625315C2 |
| APOPTOSIS-INDUCING AGENTS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2014 |
|
RU2662812C2 |
| PYRAZINONE DERIVATIVES AND USE THEREOF IN TREATMENT OF LUNG DISEASES | 2008 |
|
RU2479580C2 |
| APOPTOSIS-INDUCING MEANS FOR TREATMENT OF MALIGNANT TUMOUR AND IMMUNE AND AUTOIMMUNE DISEASES | 2015 |
|
RU2628885C2 |
| APOPTOSIS INDUCING AGENTS SELECTIVE FOR Bcl-2 FOR CANCER AND IMMUNE DISEASES TREATMENT | 2013 |
|
RU2621052C2 |
| DERIVATIVES OF PIPERAZINE, METHOD FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION AND METHOD FOR VOMITING INHIBITION | 1999 |
|
RU2258068C2 |
